These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29659040)

  • 21. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
    Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
    Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine.
    Hwang KL; Song MK; Shin HJ; Na HJ; Shin DH; Kim JK; Moon JH; Ahn JS; Song IC; Hong J; Lee GW; Chung JS
    Blood Res; 2014 Dec; 49(4):234-40. PubMed ID: 25548756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype.
    Wudhikarn K; Van Rheeden R; Leopold C; Rattanaumpawan P; Gingrich R; de Magalhaes Silverman M
    Eur J Haematol; 2012 Oct; 89(4):294-301. PubMed ID: 22762733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monosomal karyotype of chromosome 5/7 was an independent poor prognostic factor for Chinese myelodysplastic syndrome patients.
    Zhang T; Xu Y; Pan J; Qiu H; Wu D; Chen S; Sun A
    Cancer Genet; 2016 Sep; 209(9):423-429. PubMed ID: 27423487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
    Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R;
    Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
    Ren Y; Wang J; Zhang H; Mei C; Ye L; Luo Y; Zhou X; Zhu S; Jiang L; Wang L; Jin J; Tong H
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):172-179. PubMed ID: 32030889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
    Reda G; Riva M; Fattizzo B; Cassin R; Giannarelli D; Pennisi M; Freyrie A; Cairoli R; Molteni A; Cortelezzi A
    Semin Hematol; 2018 Oct; 55(4):202-208. PubMed ID: 30502848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.
    Strickland SA; Sun Z; Ketterling RP; Cherry AM; Cripe LD; Dewald G; Fernandez HF; Hicks GA; Higgins RR; Lazarus HM; Litzow MR; Luger SM; Paietta EM; Rowe JM; Vance GH; Wiernik P; Wiktor AE; Zhang Y; Tallman MS;
    Leuk Res; 2017 Aug; 59():55-64. PubMed ID: 28551161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
    Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L
    Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients.
    Belli CB; Bengió R; Aranguren PN; Sakamoto F; Flores MG; Watman N; Nucifora E; Prates MV; Arbelbide J; Larripa I
    Am J Hematol; 2011 Jul; 86(7):540-5. PubMed ID: 21674572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes.
    Kelaidi C; Tzannou I; Baltadakis I; Batsis I; Mallouri D; Spyridonidis A; Gigantes S; Tsirigotis P; Apostolidis I; Athanasiadou A; Manola K; Anagnostopoulos A; Harhalakis N; Sakellari I; Karakasis D
    Bone Marrow Transplant; 2014 Aug; 49(8):1022-8. PubMed ID: 24797183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
    Kim DY; Lee JH; Lee JH; Lee KH; Kim YK; Ahn JS; Kim HJ; Kim I; Yoon SS; Park S; Bae SH; Bang SM; Lee HG; Shin HJ; Lee JH; Min YH; Won JH; Mun YC; Oh D;
    Ann Hematol; 2010 Jan; 89(1):15-23. PubMed ID: 19543727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).
    Wierzbowska A; Wawrzyniak E; Siemieniuk-Rys M; Kotkowska A; Pluta A; Golos A; Robak T; Szarawarska M; Jaskowiec A; Duszenko E; Rybka J; Holojda J; Grosicki S; Pienkowska-Grela B; Woroniecka R; Ejduk A; Watek M; Wach M; Mucha B; Skonieczka K; Czyzewska M; Jachalska A; Klonowska A; Iliszko M; Knopinska-Posluszny W; Jarmuz-Szymczak M; Przybylowicz-Chalecka A; Gil L; Kopacz A; Holowiecki J; Haus O
    Leuk Lymphoma; 2017 Apr; 58(4):889-897. PubMed ID: 27561449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.
    Scalzulli E; Molica M; Alunni Fegatelli D; Colafigli G; Rizzo L; Mancini M; Efficace F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1919-1925. PubMed ID: 31168652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
    Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ;
    Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
    Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.